Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17051575 | 0.80 | NPC1 (0.44) | MAPTMEN1POLBKMT2ALMNA | |
| SCHEMBL13637168 | 0.79 | RAB9A (0.46) | MAPTPOLBLMNANFKB1NPC1 | |
| SCHEMBL13625508 | 0.79 | NPC1 (0.44) | XDHDHODHMAPTPOLBLMNA | |
| SCHEMBL6677218 | 0.78 | HRH3 (0.48) | MAPTLMNANFKB1NPC1RAB9A | |
| SCHEMBL12970083 | 0.78 | FYN (0.41) | MAPTLMNANFKB1NPC1RAB9A | |
| SCHEMBL11994522 | 0.76 | RAB9A (0.42) | DHODHMAPTMEN1KMT2ALMNA | |
| SCHEMBL10000239 | 0.74 | NPC1 (0.53) | MAPTMEN1POLBKMT2ALMNA | |
| SCHEMBL25455888 | 0.74 | XDH (0.46) | XDHDHODHMAPTMEN1POLB | |
| SCHEMBL13625507 | 0.74 | XDH (0.42) | XDHDHODHMAPTMEN1POLB | |
| SCHEMBL765757 | 0.74 | CCR1 (0.50) | XDHDHODHMAPTMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | XDH 3375/4885DHODH 1413/4885MAPT 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.